吉峯科技(300022.SZ):股東王新明、王紅豔、山南神宇擬減持合計不超3%股份
格隆匯6月9日丨吉峯科技(300022.SZ)公佈,公司近日收到持股5%以上股東王新明先生、王紅豔女士、西藏山南神宇創業投資管理合夥企業(有限合夥)(簡稱“山南神宇”)出具的《關於股份減持計劃的吿知函》。王新明先生、王紅豔女士、山南神宇計劃於減持計劃公吿之日起15個交易日後的三個月內以集中競價交易、大宗交易的方式合計減持公司股份不超過14,827,211股(佔公司總股本比例3.00%)。其中,以集中競價方式進行減持的,減持股份總數不超過公司總股本的1%;以大宗交易方式進行減持的,減持股份總數不超過公司總股本的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.